Trizepatide 10mg - (mounjaro)

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Its unique dual action enhances insulin secretion, improves insulin sensitivity, slows gastric emptying, and reduces appetite. Clinical studies have shown several key benefits:

• Blood sugar control – Significant reductions in HbA1c for adults with type 2 diabetes.

• Weight loss – Demonstrated greater and more sustained weight reduction compared to existing GLP-1 therapies.

• Cardiometabolic health – Improves insulin resistance, supports blood pressure reduction, and lowers cardiovascular risk factors.

• Convenience – Once-weekly dosing increases patient adherence and treatment consistency.